Blood loss ‐ Tranexamic acid versus control (litre) · Patients with liver transplantation.
1 finding from 1 review
Blood loss ‐ Thromboelastography versus control (litre) · Patients with liver transplantation.
1 finding from 1 review
Blood loss ‐ Tranexamic acid versus aprotinin · Patients with liver transplantation.
1 finding from 1 review
Blood transfusion (red cell or whole blood) · Patients with liver transplantation.
5 findings from 1 review
no estimate extracted
8 studies · 375 participants
Very low
no estimate extracted
4 studies · 159 participants
Very low
no estimate extracted
2 studies · 221 participants
Very low
Show 2 more findings
60‐day mortality ‐ Tranexamic acid versus control · Patients with liver transplantation.
It is very uncertain whether intervention changes 60‐day mortality ‐ Tranexamic acid versus control compared with control (very low certainty).
1 finding from 1 review
60‐day mortality ‐ Recombinant factor VIIa (rFVIIa) versus control · Patients with liver transplantation.
It is very uncertain whether intervention changes 60‐day mortality ‐ Recombinant factor VIIa (rFVIIa) versus control compared with control (very low certainty).
1 finding from 1 review
60‐day mortality ‐ Tranexamic acid versus aprotinin · Patients with liver transplantation.
It is very uncertain whether intervention changes 60‐day mortality ‐ Tranexamic acid versus aprotinin compared with control (very low certainty).
1 finding from 1 review
Primary graft non‐function ‐ Aprotinin versus control · Patients with liver transplantation.
It is very uncertain whether intervention changes primary graft non‐function ‐ Aprotinin versus control compared with control (very low certainty).
1 finding from 1 review
Retransplantation ‐ Aprotinin versus control · Patients with liver transplantation.
It is very uncertain whether intervention changes retransplantation ‐ Aprotinin versus control compared with control (very low certainty).
1 finding from 1 review
Retransplantation ‐ Tranexamic acid versus control · Patients with liver transplantation.
It is very uncertain whether intervention changes retransplantation ‐ Tranexamic acid versus control compared with control (very low certainty).
1 finding from 1 review
Thromboembolic events · Patients with liver transplantation.
It is very uncertain whether intervention changes thromboembolic episodes ‐ Aprotinin versus control compared with control (very low certainty).
2 findings from 1 review
All‐cause mortality · patients with primary biliary cirrhosis.
It is very uncertain whether bisphosphonates changes all‐cause mortality compared with placebo or no intervention (very low certainty).
1 finding from 1 review
Adverse events · patients with primary biliary cirrhosis.
It is very uncertain whether bisphosphonates changes adverse events compared with another bisphosphonate (very low certainty).
1 finding from 1 review
Lumbar spine bone mineral density (BMD) · patients with primary biliary cirrhosis.
1 finding from 1 review
Hip/femoral bone mineral density (BMD) · patients with primary biliary cirrhosis.
1 finding from 1 review
Procollagen type 1 N‐terminal propeptide (ng/mL) · patients with primary biliary cirrhosis.
1 finding from 1 review
The urinary amino telopeptides of collagen I (NTx) (nmol bone collagen equivalents /mmol creatinine) · patients with primary biliary cirrhosis.
1 finding from 1 review
Fracture · patients with primary biliary cirrhosis.
It is very uncertain whether bisphosphonates changes fractures compared with placebo or no intervention (very low certainty).
1 finding from 1 review
Adverse events · patients with primary biliary cirrhosis.
It is very uncertain whether bisphosphonates changes adverse events compared with placebo or no intervention (very low certainty).
1 finding from 1 review
Lumbar spine bone mineral density (BMD) · patients with primary biliary cirrhosis.
1 finding from 1 review